Document:

Exhibit 10.1 Stock Option Award Agreement

    Exhibit
      10.1

    
      

    

    

    AWARD
      AGREEMENT

    

    pursuant
      to the

    

    2006
      INCENTIVE STOCK PLAN OF

    VINEYARD
      NATIONAL BANCORP

    *
      * * * *

    

    Participant:
      Norman A Morales

    

    Grant
      Date: October 30, 2006

    

    Number
      of 

    Options
      inc. type, SARs, Restricted Shares Granted: 50,000 options

    

    Exercise/Base
      Price (per share): Closing price on 10/30/06

    

    Expiration
      Date: 4
      years from Grant Date 

    

    Vesting
      Schedule:  three
      (3)
      years from the date of option grant    

    

    *
      * * * *

    

    THIS
      AWARD AGREEMENT
      (this
“Agreement”), dated as of the Grant Date specified above, is entered into by and
      between Vineyard National Bancorp, (the “Company”), and the Participant
      specified above, pursuant to the Vineyard National Bancorp 2006 Incentive Stock
      Plan as in effect and as amended from time to time (the “Plan”);
      and

    

    WHEREAS,
      it has
      been determined under the Plan that it would be in the best interests of the
      Company to grant the Award provided herein to the Participant.

    

    NOW,
      THEREFORE,
      in
      consideration of the mutual covenants and premises hereinafter set forth and
      for
      other good and valuable consideration, the parties hereto hereby mutually
      covenant and agree as follows:

    

    1.  Incorporation
      By Reference; Plan Document Receipt.
      This
      Agreement is subject in all respects to the terms and provisions of the Plan
      (including, without limitation, any amendments thereto adopted at any time
      and
      from time to time unless such amendments are expressly intended not to apply
      to
      the award provided hereunder), all of which terms and provisions are made a
      part
      of and incorporated in this Agreement as if they were expressly set forth
      herein. Any capitalized term not defined in this Agreement shall have the same
      meaning as is ascribed thereto in the Plan. The Participant hereby acknowledges
      receipt of a true copy of the Plan and that the Participant has read the Plan
      carefully and fully understands its content. In the event of a conflict between
      the terms of this Agreement and the terms of the Plan, the terms of the Plan
      shall control.

     

    
      
        
        

      

      
        1

        
          

        

      

      
        
        

      

    

     

    2.  Grant
      of Award.
      The
      Company hereby grants to the Participant, as of the Grant Date specified above,
      the Award specified above. Except as otherwise provided by Section 9.1 of the
      Plan, the Participant agrees and understands that nothing contained in this
      Agreement provides, or is intended to provide, the Participant with any
      protection against potential future dilution of the Participant’s stockholder
      interest in the Company for any reason.

     

    3.  Vesting.
      

     

    3.1  The
      Award
      covered by this grant shall become unrestricted and fully vested on the
      third (3rd) anniversary of the date of option grant, and then being one hundred
      percent (100%) vested,
      provided the Participant is then employed by the Company and/or one of its
      Subsidiaries or serves as a director of the Company and/or one of its
      Subsidiaries. 

     

    3.2  If
      the
      Participant’s employment with the Company and/or its Subsidiaries terminates for
      any reason (other than due to Disability, Retirement or death) prior to the
      vesting of all or any portion of the Award covered by this Agreement, such
      unvested Award shall immediately be cancelled and the Participant (and the
      Participant’s estate, designated beneficiary or other legal representative)
      shall forfeit any rights or interests in and with respect to any such unvested
      Award. The Board or the Committee, in its sole discretion, may determine, prior
      to or within ninety (90) days after the date of any such termination, that
      all
      or a portion of the Participant’s unvested Award shall not be so cancelled and
      forfeited. 

     

    3.3  If
      the
      Participant’s employment with the Company and/or its Subsidiaries terminates due
      to the Participant's death, Disability or Retirement, the Participant shall
      become 100% vested in the Award granted under this Agreement as of the date
      of
      any such termination.

     

    3.3.1  For
      purposes of this Agreement, “Disability” means disability as defined in the
      Participant’s then effective employment agreement, or if the Participant is not
      then a party to an effective employment agreement with the Company which defines
      disability, “Disability” means disability as determined by the Board in
      accordance with standards and procedures similar to those under the Company’s
      long-term disability plan, if any. Subject to the first sentence of this Section
      3.3.1, at any time that the Company does not maintain a long-term disability
      plan, “Disability” shall mean any physical or mental disability which is
      determined to be total and permanent by a physician selected in good faith
      by
      the Company.

     

    3.3.2  For
      purposes of this Agreement, “Retirement” means the voluntary retirement by the
      Participant from active employment with the Company and its Subsidiaries on
      or
      after the attainment of Normal Retirement Age under Company-sponsored pension
      or
      retirement plans, or any other age with the consent of the Board.

     

    3.4  If
      the
      Participant's employer ceases to be a Subsidiary of the Company, that event
      shall be deemed to constitute a termination of employment under section 3.2
      above.

     

    4.  Non-transferability.
      Awards,
      and any rights and interests with respect thereto, issued under this Agreement
      and the Plan shall not, prior to vesting, be sold, exchanged, transferred,
      assigned or otherwise disposed of in any way by the Participant (or any
      beneficiary(ies) of the Participant), other than by testamentary disposition
      by
      the Participant or the laws of descent and distribution. Any such Award, and
      any
      rights and interests with respect thereto, shall not, prior to vesting, be
      pledged, encumbered or otherwise hypothecated in any way by the Participant
      (or
      any beneficiary(ies) of the Participant) and shall not, prior to vesting, be
      subject to execution, attachment or similar legal process. Any attempt to sell,
      exchange, transfer, assign, pledge, encumber or otherwise dispose of or
      hypothecate in any way any portion or all of an Award, or the levy of any
      execution, attachment or similar legal process upon the Award, contrary to
      the
      terms and provisions of this Agreement and/or the Plan shall be null and void
      and without legal force or effect.

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    5.  Entire
      Agreement; Amendment.
      This
      Agreement, together with the Plan, contains the entire agreement between the
      parties hereto with respect to the subject matter contained herein, and
      supersedes all prior agreements or prior understandings, whether written or
      oral, between the parties relating to such subject matter. This Agreement may
      only be modified or amended by a writing signed by both the Company and the
      Participant.

     

    6.  Notices.
      Any
      notice which may be required or permitted under this Agreement shall be in
      writing and shall be delivered in person, or via facsimile transmission,
      overnight courier service or certified mail, return receipt requested, postage
      prepaid, properly addressed as follows:

     

    6.1  If
      such
      notice is to the Company, to the attention of the Director of Corporate Services
      of Vineyard National Bancorp, 1260 Corona Pointe Court, Corona, CA 92879, or
      at
      such other address as the Company, by notice to the Participant, shall designate
      in writing from time to time.

     

    6.2  If
      such
      notice is to the Participant, at his or her address as shown on the Company’s
      records, or at such other address as the Participant, by notice to the Company,
      shall designate in writing from time to time.

     

    7.  Governing
      Law.
      This
      Agreement shall be governed by and construed in accordance with the laws of
      the
      State of California, without reference to the principles of conflict of laws
      thereof. 

     

    8.  Compliance
      with Laws.
      The
      issuance of the Award pursuant to this Agreement shall be subject to, and shall
      comply with, any applicable requirements of any federal and state securities
      laws, rules and regulations (including, without limitation, the provisions
      of
      the Securities Act of 1933, the Exchange Act and the respective rules and
      regulations promulgated thereunder) and any other law or regulation applicable
      thereto. The Company shall not be obligated to issue any Shares or Common Stock
      subject to an Award pursuant to this Agreement if such issuance would violate
      any such requirements. 

     

    9.  Binding
      Agreement; Assignment.
      This
      Agreement shall inure to the benefit of, be binding upon, and be enforceable
      by
      the Company and its successors and assigns. The Participant shall not assign
      any
      part of this Agreement without the prior express written consent of the
      Company.

     

    10.  Counterparts.
      This
      Agreement may be executed in one or more counterparts, each of which shall
      be
      deemed to be an original, but all of which shall constitute one and the same
      instrument.

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    11.  Headings.
      The
      titles and headings of the various sections of this Agreement have been inserted
      for convenience of reference only and shall not be deemed to be a part of this
      Agreement.

     

    12.  Further
      Assurances.
      Each
      party hereto shall do and perform (or shall cause to be done and performed)
      all
      such further acts and shall execute and deliver all such other agreements,
      certificates, instruments and documents as any other party hereto reasonably
      may
      request in order to carry out the intent and accomplish the purposes of this
      Agreement and the Plan and the consummation of the transactions contemplated
      thereunder.

     

    13.  Severability.
      The
      invalidity or unenforceability of any provisions of this Agreement in any
      jurisdiction shall not affect the validity, legality or enforceability of the
      remainder of this Agreement in such jurisdiction or the validity, legality
      or
      enforceability of any provision of this Agreement in any other jurisdiction,
      it
      being intended that all rights and obligations of the parties hereunder shall
      be
      enforceable to the fullest extent permitted by law.

     

    IN
      WITNESS WHEREOF,
      the
      Company has caused this Agreement to be executed by its duly authorized officer,
      and the Participant has hereunto set his hand, all as of the Grant Date
      specified above.

    

    VINEYARD
      NATIONAL BANCORP

    

    

    By:
      _____________________________

    Name:
      Frank Alvarez 

    Title:
      Chairman of the Board

    

    

    

    

    _________________________________

    Norman
      Morales

    President
      and Chief Executive Officer

    

    
      
        
        

      

      
        4Exhibit 10.1

    Exhibit
      10.1

     

    Execution
      Copy

     

    

      AMENDMENT
        NO. 1 TO
        THE 

      COLLABORATION
        AND
        LICENSE AGREEMENT

      

      This
        Amendment No. 1 to
        the Collaboration and License Agreement (this “Amendment”) is dated as of August
        31, 2006 (the “Amendment Effective Date”) by and between ImmunoGen, Inc., a
        Massachusetts corporation with a principal office at 128 Sidney Street,
        Cambridge, Massachusetts 02139 (“ImmunoGen”), and sanofi-aventis U. S. LLC, a
        Delaware limited liability company with a offices at 1041 Rt. 202-206,
        Bridgewater, NJ 08807 (“sanofi-aventis”). Capitalized terms used but not
        otherwise defined herein shall have the meanings ascribed to such terms in
        the
        Collaboration and License Agreement (the “Agreement”) dated as of July 30, 2003
        (the “Agreement Effective Date”) by and between ImmunoGen and Aventis
        Pharmaceuticals, Inc. (“Aventis”).

      

      WHEREAS,
        on the Agreement
        Effective Date, ImmunoGen and Aventis, the predecessor in interest to
        sanofi-aventis, entered into the Agreement for the purpose of collaborating
        on
        the identification and validation of targets for use in the discovery of
        antibodies and antibody-drug conjugates in the Collaborative Focus Area (as
        defined in the Agreement) and in the development and commercialization of
        such
        antibodies and antibody-drug conjugates; and

      

      WHEREAS,
        the Parties
        hereto desire to amend the Agreement as set forth herein and to set forth
        certain additional terms applicable to the Agreement, as so
        amended.

      

      NOW,
        THEREFORE, in
        consideration of the mutual covenants contained herein, and for other good
        and
        valuable consideration, the Parties hereto, intending to be legally bound,
        hereby agree as follows:

      

      1. Amendments
        to
        Agreement.

       

       

      (a) Section
        1.20 of the
        Agreement is hereby deleted in its entirety and replaced with the
        following:

      

      “1.20 “Collaboration
        Product”
        means any product, other than a Licensed Product, containing a Program
        Antibody.”

      

      b) A
        new Section 2.14 is
        hereby added to the Agreement which shall provide as follows:

      

      “2.14 Collaboration
        Portfolio.
        For purposes of clarity
        (a) Schedule
        2.14
        attached hereto lists all Antibody Targets, Program Targets, Program Targets
        with Program Antibodies and Program Targets with Lead Antibodies that are
        part
        of the Research Program as of the Amendment Effective Date. The Joint Research
        Committee shall update and amend, as appropriate, the then current Schedule
        2.14
        as
        necessary during each Contract Year and on the expiration of the Research
        Program Term in order to list all Antibody Targets, Program Targets, Program
        Targets with Program Antibodies, Program Targets with Lead Antibody and Program
        Targets with Lead Antibody in

    

     

     

    
      
        

          Portions
            of this
            Exhibit were omitted and have been filed separately with the Secretary
            of the
            Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Development
      at that point
      in time. In addition to those Program Targets for which Program Antibodies
      have
      already been generated, it is anticipated that Program Antibodies shall have
      been generated prior to the expiration of the Research Program Term, for [***],
      [***] and [***].”

     

    (c) Section
      2.8.1 of the
      Agreement is hereby amended by adding the following sentence at the end of
      such
      provision:

    

    “Notwithstanding
      the
      foregoing, the Parties hereby agree that during the period commencing on the
      Amendment Effective Date and continuing until the expiration of the Research
      Program Term, (a) neither Party shall have the obligation under this Agreement
      to identify or provide Targets for use in the Research Program and the Parties
      will focus on progressing the Targets and Antibodies listed in Schedule 2.14
      as
      more specifically described in the Research Plan for the remainder of the
      Research Program Term and (b) Aventis shall have the right to identify and
      provide new Targets for use in the Research Program pursuant to Section 2.8.2
      below only to the extent that (i) the estimated number of FTEs to be provided
      by
      ImmunoGen under Section 2.5.1 for a particular Calendar Quarter is estimated
      to
      fall short of the number of FTEs set forth in the Annual Research Plan for
      such
      Calendar Quarter and (ii) ImmunoGen is not engaged in its own program outside
      of
      the collaboration on any such new Targets. Further, all Targets identified
      pursuant to the [***] [***] [***] [***] with [***] [***] [***], including any
      [***] [***] [***] [***] [***] during the Research Program Term, related to
      development of murine monoclonal antibodies that selectively recognize novel
      antigens in human tissues, shall be provided for use in the Research Program
      and
      shall be designated Program Targets pursuant to Section 2.8.2
      below.”

     

    (d) Section
      7.1.2 of the
      Agreement is hereby deleted in its entirety and replaced with the
      following:

     

    “7.1.2
Development
      Licenses.
      With respect to all Program Targets for which Program Antibodies have been
      developed prior to the expiration of the Research Program Term, ImmunoGen hereby
      grants to Aventis and its Affiliates, subject to Section 7.1.8 below, an
      exclusive (even as to ImmunoGen and its Affiliates), worldwide, royalty-free
      license, with the right to grant sublicenses to Approved Subcontractors, under
      ImmunoGen Intellectual Property, to Develop Products.”

     

    (e) Section
      7.5.2 of the
      Agreement is hereby deleted in its entirety. 

    

     

    2. Miscellaneous. The
      Parties acknowledge
      that in connection with the internal restructuring of the sanofi-aventis Group
      in the United States, certain assets and liabilities of Aventis, including
      its
      rights and obligations under the Agreement, were contributed to,
      and

     

    
      
        2

      

      
        
          Portions
            of this
            Exhibit were omitted and have been filed separately with the Secretary
            of the
            Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 24b-2 of the Securities Exchange Act of
            1934.

        

        
          

        

      

      
        
        

      

    

     

    

      assumed
        by, sanofi-aventis
        U.S. LLC, a limited liability company of which Aventis is a member. The Parties
        hereby confirm and agree that, except as amended hereby, the Agreement remains
        in full force and effect and is a binding obligation of the Parties hereto.
        This
        Amendment may be executed in counterparts, each of which shall be deemed
        an
        original, but all of which together shall constitute one and the same
        instrument.

      

      IN
        WITNESS WHEREOF, the
        Parties have caused this Amendment to be executed by their duly authorized
        representatives.

       

       

      
        	 IMMUNOGEN, INC.	 	 SANOFI-AVENTIS U.S.
                LLC
	 	 	 	 	 
	 By: 	 	 	 By:	 
	 Name:	 	 	 Name:	 
	 Title:	 	 	 Title:	 
	 	                                 	 	 	 
	 	 	 	 	 
	 	 	 	 By:	 
	 	 	 	 Name:	 
	 	 	 	 Title:	 
	 	 	 	 	 

      

       

       

      
        
          
            3

          

        

        
          
            Portions
              of this
              Exhibit were omitted and have been filed separately with the Secretary
              of the
              Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 24b-2 of the Securities Exchange Act of
              1934.

          

          
            

          

        

        
          
          

        

      

    

    Schedule
      2.14

    
      

      [COLLABORATION
        PORTFOLIO AS OF AMENDMENT EFFECTIVE DATE

      

      

      
        	
                Antibody
                  Targets

              	
                Program
                  Target 

              	
                Program
                  Targets

                with
                  Program
                  

                Antibodies

              	
                Program
                  Targets 

                with
                  Lead
                  Antibody

              	
                Program
                  Targets 

                with
                  Lead
                  Antibody in Development

              
	
                [***]
                  [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                CD
                  33 (AVE9633)

              
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                CD
                  19 (SAR3419)

              
	
                [***]

              	
                [***]

              	
                [***]

              	 	
                IGF-1R
                  (AVE1642)

              
	
                [***]

              	 	
                [***]

              	 	 
	
                [***]

              	 	
                [***]

              	 	 
	
                [***]

              	 	
                [***]

              	 	 
	 	 	
                [***]

              	 	 
	 	 	
                [***]

              	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

      

      

      
        
          4

        

        
          
            Portions
              of this
              Exhibit were omitted and have been filed separately with the Secretary
              of the
              Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 24b-2 of the Securities Exchange Act of
              1934.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}]]